2014
DOI: 10.1146/annurev-pharmtox-011613-140028
|View full text |Cite
|
Sign up to set email alerts
|

Targeting Protein-Protein Interaction by Small Molecules

Abstract: Protein-protein interactions (PPIs) are critical regulatory events in physiology and pathology, and they represent an important target space for pharmacological intervention. However, targeting PPIs with small molecules is challenging owing to the large surface area involved in protein-protein binding and the lack of obvious small-molecule-binding pockets at many protein-protein interfaces. Nonetheless, successful examples of small-molecule modulators of PPIs have been growing in recent years. This article rev… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
136
0
2

Year Published

2014
2014
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 173 publications
(138 citation statements)
references
References 114 publications
0
136
0
2
Order By: Relevance
“…Yet there is increasing evidence that small molecules that effectively dock onto hotspots of the interaction sites between partners and thus inhibit their interactions can indeed be found (reviewed in ref. 48). Such hotspots have been reported for the b-catenin/TCF4 interaction (32,37).…”
Section: Discussionmentioning
confidence: 99%
“…Yet there is increasing evidence that small molecules that effectively dock onto hotspots of the interaction sites between partners and thus inhibit their interactions can indeed be found (reviewed in ref. 48). Such hotspots have been reported for the b-catenin/TCF4 interaction (32,37).…”
Section: Discussionmentioning
confidence: 99%
“…Therapeutic targeting of PPIs offers an attractive alternative to classical drug targets in cases where the target of interest does not exhibit any enzymatic activity or ligand binding site that can be easily targeted and because of the large number of potential PPI targets (39). Indeed PPIs represent an emerging class of drug targets and there is a growing interest in technologies that allow screening for small molecule disruptors of PPIs.…”
Section: Discussionmentioning
confidence: 99%
“…The GPCR-TRP Axis protein-protein interactions have had limited success owing to difficulty in disrupting the large interfaces between interacting proteins (Jin et al, 2014). However, several approaches that have been explored to disrupt such interactions may allow for TRP channelspecific inhibition.…”
Section: Therapeutic Targeting Of G Protein-coupled Receptor-transmentioning
confidence: 99%